|From: singhtelecom (Rep: 959)||Date: 09/26/2018 03:47|
|Forum: AVEO Pharmaceuticals, Inc. - Msg #768||Thread #674037156 (Rec: 0) |
|announced that it's presenting at two investor conferences hosted by investment banks Cantor Fitzgerald and Leerink Partners next week.|
AVEO has already said it plans to present phase 2 data testing its drug ficlatuzumab and Eli Lilly's Erbitux in patients with head and neck squamous cell carcinoma that has spread to other parts of the body.
Investors will get a first look at the data on Oct. 9 when the abstract for the presentation is released.
But keep in mind that this is an ongoing study and the abstracts had to be submitted months ago, so whatever data is in the abstract is likely to be a fraction of what will be presented at the conference.
In addition the ESMO presentation, investors are also waiting for data from the Tivo-3 study testing its lead drug tivozanib in patients with advanced renal cell carcinoma, a type of kidney cancer.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.